TRAVERE THERAPEUTICS INC (TVTX) Stock Overview
NASDAQ:TVTX - US89422G1076 - Common Stock
TVTX Key Statistics, Chart & Performance
The current stock price of TVTX is 19.61 USD. In the past month the price increased by 17.57%. In the past year, price increased by 78.6%.
TVTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.01 | 374.26B | ||
| AMGN | AMGEN INC | 13.01 | 152.81B | ||
| GILD | GILEAD SCIENCES INC | 14.6 | 140.20B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.41 | 101.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.35 | 59.76B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.65B | ||
| ARGX | ARGENX SE - ADR | 77.89 | 44.19B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.78 | 39.97B | ||
| INSM | INSMED INC | N/A | 30.33B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.14B | ||
| NTRA | NATERA INC | N/A | 22.99B | ||
| BIIB | BIOGEN INC | 8.85 | 20.76B |
Related stock screener links
About TVTX
Company Profile
Travere Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 385 full-time employees. The company went IPO on 2003-07-23. The firm is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Company Info
TRAVERE THERAPEUTICS INC
3611 Valley Centre Dr, Suite 300
San Diego CALIFORNIA 92130 US
CEO: Eric M. Dube
Employees: 385
Phone: 18889697879
TRAVERE THERAPEUTICS INC / TVTX FAQ
What is the stock price of TRAVERE THERAPEUTICS INC today?
The current stock price of TVTX is 19.61 USD. The price increased by 8.04% in the last trading session.
What is the ticker symbol for TRAVERE THERAPEUTICS INC stock?
The exchange symbol of TRAVERE THERAPEUTICS INC is TVTX and it is listed on the Nasdaq exchange.
On which exchange is TVTX stock listed?
TVTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for TRAVERE THERAPEUTICS INC stock?
22 analysts have analysed TVTX and the average price target is 34.76 USD. This implies a price increase of 77.25% is expected in the next year compared to the current price of 19.61. Check the TRAVERE THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is TRAVERE THERAPEUTICS INC worth?
TRAVERE THERAPEUTICS INC (TVTX) has a market capitalization of 1.75B USD. This makes TVTX a Small Cap stock.
How many employees does TRAVERE THERAPEUTICS INC have?
TRAVERE THERAPEUTICS INC (TVTX) currently has 385 employees.
What are the support and resistance levels for TRAVERE THERAPEUTICS INC (TVTX) stock?
TRAVERE THERAPEUTICS INC (TVTX) has a support level at 17.88. Check the full technical report for a detailed analysis of TVTX support and resistance levels.
Is TRAVERE THERAPEUTICS INC (TVTX) expected to grow?
The Revenue of TRAVERE THERAPEUTICS INC (TVTX) is expected to grow by 80.63% in the next year. Check the estimates tab for more information on the TVTX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy TRAVERE THERAPEUTICS INC (TVTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TVTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TVTX, evaluating the profitability, health, valuation and growth aspects
- TRAVERE THERAPEUTICS INC (TVTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- TRAVERE THERAPEUTICS INC (TVTX) Sales and EPS estimates to see what analysts future expectations are.
- TRAVERE THERAPEUTICS INC (TVTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- TRAVERE THERAPEUTICS INC (TVTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- TRAVERE THERAPEUTICS INC (TVTX) Stock Chart to make your own analysis
- TRAVERE THERAPEUTICS INC (TVTX) Latest news and press-releases to stay up to date.
Does TRAVERE THERAPEUTICS INC (TVTX) stock pay dividends?
TVTX does not pay a dividend.
When does TRAVERE THERAPEUTICS INC (TVTX) report earnings?
TRAVERE THERAPEUTICS INC (TVTX) will report earnings on 2025-10-29, after the market close.
What is the Price/Earnings (PE) ratio of TRAVERE THERAPEUTICS INC (TVTX)?
TRAVERE THERAPEUTICS INC (TVTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.04).
What is the Short Interest ratio of TRAVERE THERAPEUTICS INC (TVTX) stock?
The outstanding short interest for TRAVERE THERAPEUTICS INC (TVTX) is 14.11% of its float. Check the ownership tab for more information on the TVTX short interest.
TVTX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to TVTX. When comparing the yearly performance of all stocks, TVTX is one of the better performing stocks in the market, outperforming 91.99% of all stocks.
TVTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TVTX. Both the profitability and financial health of TVTX have multiple concerns.
TVTX Financial Highlights
Over the last trailing twelve months TVTX reported a non-GAAP Earnings per Share(EPS) of -2.04. The EPS increased by 58.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -30.44% | ||
| ROE | -516.25% | ||
| Debt/Equity | 9.5 |
TVTX Forecast & Estimates
22 analysts have analysed TVTX and the average price target is 34.76 USD. This implies a price increase of 77.25% is expected in the next year compared to the current price of 19.61.
For the next year, analysts expect an EPS growth of 72.11% and a revenue growth 80.63% for TVTX